Carboplatin News and Research

RSS

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).

Research: Paragazole makes triple-negative breast cancer cells express estrogen receptors

Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast cancer cells express estrogen receptors, and that increases the sensitivity of these cells to chemotherapy.

9 Apr 2013

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).

28 Mar 2013

Children with low-risk retinoblastoma do not need postoperative chemotherapy

New results from a prospective clinical trial conducted in France show that children with low-risk retinoblastoma do not need postoperative (adjuvant) chemotherapy to prevent disease recurrence or metastasis; the results also suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment, or perhaps forego it altogether. Avoiding chemotherapy spares patients from treatment side effects and long-term health risks, such as cardiovascular disease and development of a second cancer.

5 Mar 2013

PDL BioPharma fourth quarter total revenues increase to $86.0 million

PDL BioPharma, Inc. (PDL) today reported financial results for the fourth quarter and full year ended December 31, 2012.

2 Mar 2013

Positive data from Oncolytics' REOLYSIN Phase 2 combination trial on SCCLC

Oncolytics Biotech Inc. today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021).

9 Feb 2013

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

5 Feb 2013

Bevacizumab QoL impact highlighted in ovarian cancer patients

The ICON7 study results suggest that improved progression-free survival with bevacizumab therapy for high-risk ovarian cancer may come at the cost of health-related quality of life.

21 Jan 2013

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

Morphotek Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse.

11 Jan 2013

$Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer$

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.

3 Jan 2013

Positive data from Oncolytics’ REOLYSIN Phase III combination study on head and neck cancers

Oncolytics Biotech Inc. today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018).

13 Dec 2012

Viruses to treat metastatic cancers

There exists a "type" of cancer that is common yet rarely discussed—metastatic cancer, or cancer that has spread from the part of the body where it originated (the primary tumor) to another (such as lungs, bones or liver). Although much research is being done to combat primary tumors, there still exists a crucial need to find a treatment that can be effective against metastatic cancer, or "mets." Could a virus be the answer that finally beats the mets?

15 Nov 2012

Treatment rate high at end of life for prostate cancer patients

Approximately one-third of men with castration-resistant prostate cancer receive some form of treatment in the last 3 months of life, show US study results.

1 Nov 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

New type of drug for drug-resistant cancer

New drug may be an effective alternative for patients whose cancer is resistant to currently available drugs.

4 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

Positive data from Aprea’s APR-246 Phase I/II study on blood or prostate cancer

Aprea today announced positive data from a completed Phase I/II clinical study with its investigational drug APR-246. The results from the study have been published in the Journal of Clinical Oncology.

18 Sep 2012

Study could reveal whether breast cancer patients with BRCA mutations are responsive to Veliparib

Ongoing research at the Methodist Cancer Center could reveal whether metastatic breast cancer patients with BRCA gene mutations are particularly responsive to a drug regimen that includes Veliparib, an investigational drug believed to hamper cancer cells.

15 Sep 2012